Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis

Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling

(2013) V O Kaminskyy et al.   Cell Death & Disease

Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

(2012) Asli Kisim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells

(2012) Shunchao Yan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells

(2011) David J Taylor et al.   BMC CANCER

Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL

(2011) Vitaliy O. Kaminskyy et al.   CARCINOGENESIS

Importin β1 Protein-mediated Nuclear Localization of Death Receptor 5 (DR5) Limits DR5/Tumor Necrosis Factor (TNF)-related Apoptosis-inducing Ligand (TRAIL)-induced Cell Death of Human Tumor Cells

(2011) Yuko Kojima et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors

(2011) V. K. Vyas et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

DHODH modulates transcriptional elongation in the neural crest and melanoma

(2011) Richard Mark White et al.   NATURE

Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL

(2010) Alena Vaculova et al.   Molecular Cancer

A Comprehensive Panel of Three-Dimensional Models for Studies of Prostate Cancer Growth, Invasion and Drug Responses

(2010) Ville Härmä et al.   PLoS One

Novel HTS Strategy Identifies TRAIL-Sensitizing Compounds Acting Specifically Through the Caspase-8 Apoptotic Axis

(2010) Darren Finlay et al.   PLoS One

The Anti-Inflammatory Drug Leflunomide Is an Agonist of the Aryl Hydrocarbon Receptor

(2010) Edmond F. O'Donnell et al.   PLoS One

Sensitization of Human Hepatic Stellate Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Leflunomide

(2009) Xiaoming Tang et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Death receptors: Targets for cancer therapy

(2009) Zafar Mahmood et al.   EXPERIMENTAL CELL RESEARCH

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

(2009) Jean E. Merrill et al.   JOURNAL OF NEUROLOGY

TRAILing death in cancer

(2009) Gregory Mellier et al.   MOLECULAR ASPECTS OF MEDICINE

Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells

(2009) P. Baumann et al.   MOLECULAR CANCER THERAPEUTICS

A cell-based high-throughput screen to identify synergistic TRAIL sensitizers

(2008) Nancy Lynn Booth et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Death receptors as targets for anti-cancer therapy

(2008) Kerstin Papenfuss et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE